Back to top
more

UnitedHealth Group (UNH)

(Delayed Data from NYSE)

$577.96 USD

577.96
3,124,914

-11.18 (-1.90%)

Updated Sep 17, 2024 04:00 PM ET

After-Market: $578.01 +0.05 (0.01%) 5:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 28% (181 out of 251)

Industry: Medical - HMOs

Better trading starts here.

Zacks News

UnitedHealth Group, Inc. is the largest health care services company in the world, serving over 50 million individuals in the United States as of 2019 and over 5 million internationally. The company provides a wide range of health care products and services, such as health maintenance organizations (HMOs), point of service plans (POS), preferred provider organizations (PPOs), and managed fee-for-service programs. UnitedHealth has the largest and most diverse membership base within the managed-care organization market, which gives it significant competitive advantages. It also has built its prescription drug business through OptumRx division, with the acquisition of Catamaran in 2015.

AmerisourceBergen (ABC) Q2 Earnings & Revenues Top Estimates

AmerisourceBergen's (ABC) fiscal second-quarter results benefit from segmental growth.

Should Vanguard Mega Cap Value ETF (MGV) Be on Your Investing Radar?

Style Box ETF report for MGV

Zimmer Biomet (ZBH) Q1 Earnings Top Estimates, FY22 View Up

Each of Zimmer Biomet's (ZBH) geographic segments and product divisions recorded year-over-year sales growth at CER.

Catalent (CTLT) Q3 Earnings Beat Estimates, FY22 View Up

Catalent's (CTLT) robust performance across most of its segments drives its third-quarter fiscal 2022 top line.

Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now

Investors are optimistic about Quest Diagnostics (DGX) owing to a strong recovery in base business and raised 2022 outlook.

Integer Holdings (ITGR) Q1 Earnings, Revenues Lag Estimates

Integer Holdings' (ITGR) first-quarter results reflect robust segmental performances besides strength in the majority of the product lines.

Integra (IART) Q1 Earnings Top Estimates, Margins Expand

Integra's (IART) updated 2022 financial guidance calls for strong year-over-year organic growth.

Syneos Health (SYNH) Q1 Earnings Top Estimates, Margins Up

Syneos Health's (SYNH) revenues increased year over year in the first quarter, led by strong performances by the Clinical Solutions and Commercial Solutions arms.

Surmodics (SRDX) Beats on Q2 Earnings, Revises FY22 View

Despite solid IVD revenues, Surmodics (SRDX) reports a soft Q2 overall top line.

Teleflex's (TFX) Q1 Earnings Top Estimates, Margins Down

Teleflex (TFX) exhibits year-over-year growth across the Americas, EMEA and Asia regions at CER in the first quarter.

Accuray (ARAY) Q3 Earnings Beat Estimates, Revenues Lag

Despite strong product demand, Accuray (ARAY) reports an overall soft Q3 performance.

Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Up

Bio-Rad's (BIO) first-quarter 2022 revenues decline year over year due to lower COVID-related demand.

QIAGEN (QGEN) Q1 Earnings Surpass Estimates, 2022 View Up

QIAGEN (QGEN) exited first-quarter 2022 with better-than-expected results on strength in the non-COVID product portfolio driving the top line.

Stryker (SYK) Q1 Earnings and Revenues Surpass Estimates

Stryker's (SYK) first-quarter earnings reflect strong performance across its segments.

DexCom (DXCM) Q1 Earnings Miss, Revenues Beat Estimates

Despite a decline in bottom line, DexCom's (DXCM) first-quarter results benefit from domestic and international revenue growth and solid new customer additions.

Merit Medical (MMSI) Q1 Earnings Beat, FY22 View Unchanged

Merit Medical (MMSI), in the first quarter, benefits from revenue growth in both its segments and from all of the product categories within its Cardiovascular unit.

Hologic (HOLX) Q2 Earnings Surpass Estimates, 2022 View Up

Hologic's (HOLX) second-quarter 2022 revenues decline year over year primarily due to lower COVID-19 assay sales compared to the prior year.

LabCorp (LH) Q1 Earnings Surpass Estimates, Revenues Miss

LabCorp (LH) reports better-than-expected earnings for the first quarter, with robust sales within the Drug Development arm driving the top line.

Thermo Fisher (TMO) Q1 Earnings Beat Estimates, Margins Down

The robust year-over-year revenue growth across Thermo Fisher's (TMO) Analytical Instruments and the Laboratory Products and Biopharma Services segments appears promising.

Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates

Baxter's (BAX) first-quarter results reflect robust performance across four of its business units.

West Pharmaceutical (WST) Q1 Earnings Top Estimates, Revenues Lag

West Pharmaceutical's (WST) first-quarter earnings reflect strength in the Proprietary Products segment and operating margin expansion.

Align Technology (ALGN) Q1 Earnings Lag Estimates, Margins Fall

Robust Clear Aligner case volume growth and increased uptake of the iTero Element 5D Plus are driving Align Technology's (ALGN) first-quarter top line.